In this paper we investigate how oral administration of very low doses of the anti-inflammatory cytokine IL-10 and an antibody raised against the pro-inflammatory cytokine IL-1 alpha confers protection against experimentally-induced inflammation in a mouse model of colitis. Here, IL10 is linked to colitis.